VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Nanofibers and VEGF hold promise for cardiovascular repair

A National Cheng Kung University research team has made a breakthrough in the regeneration of new blood vessels in cardiovascular therapy by using nanofibers and vascular endothelial growth factor.

10 Aug 2012

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Adding motesanib to carboplatin–paclitaxel does not boost overall survival in patients with advanced nonsquamous non-small-cell lung cancer, including those with adenocarcinoma, say MONET1 investigators.

8 Aug 2012

Breast cancer drug bevacizumab (Avastin): an interview with Dr Anna Dorothea Wagner

Breast cancer is the most important cancer for women in the developed world. About 20% of all patients diagnosed with breast cancer die of metastatic disease.

1 Aug 2012

Dosimetry data from SalutarisMD episcleral brachytherapy device clinical study on wet AMD

At the American Association of Physicists in Medicine (AAPM) Annual Meeting yesterday, Russell J. Hamilton, PhD, Professor and Physics Section Head, University of Arizona Department of Radiation Oncology, reviewed dosimetry data for a minimally invasive episcleral brachytherapy device developed by Salutaris Medical Devices, Inc. (SalutarisMD) to treat Wet AMD (Age-related Macular Degeneration), the leading cause of vision loss and blindness.

30 Jul 2012

FDA accepts Exelixis’ cabozantinib NDA for filing

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).

30 Jul 2012

New compound effective at blocking damage to the retina in diabetic retinopathy

Researchers at the University of Michigan Kellogg Eye Center have identified a compound that could interrupt the chain of events that cause damage to the retina in diabetic retinopathy. The finding is significant because it could lead to a novel therapy that targets two mechanisms at the root of the disease: inflammation and the weakening of the blood barrier that protects the retina.

30 Jul 2012

Hypoxic lung environment increases HIF-2a tumor growth signaling

In addition to the well-known risk factor of smoking, chronic obstructive pulmonary disease (COPD) increases lung cancer risk.

25 Jul 2012

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

24 Jul 2012

Nottingham researchers to lead Avastin clinical study for AMD

Nottingham researchers are leading a study to test the effectiveness of a controversial drug in the treatment of a common loss of vision.

12 Jul 2012

Breast cancer drug bevacizumab slows progression but has no overall survival benefit

The cancer drug bevacizumab (Avastin®) offers only a modest benefit in prolonging disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researchers. The researchers assessed the efficacy of bevacizumab in combination with chemotherapy, an established cancer treatment in this indication, and found no overall survival benefit when adding bevacizumab to chemotherapy.

11 Jul 2012

Biomarkers predict benefit of targeted therapy in metastatic renal-cell cancer

In metastatic renal-cell cancer, the level of cytokines and angiogenic factors identify those patients with an aggressive disease course who derive the greatest benefit from treatment with the molecular-targeted therapy pazopanib, a retrospective analysis of clinical trials shows.

10 Jul 2012

Cancer Therapeutics announces validation and performance of CTx-294886 plus Avastin

5 Jul 2012

Cancer Therapeutics reveals proof of concept for second development drug

Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin™ (bevacizumab – Genentech/Roche) in a preclinical model of breast cancer. At the same time the Company announced that it has developed a new High Throughput Screening (HTS) platform for the identification of small molecule inhibitors of protein ubiquitination, a key element in the essential cellular process of protein homeostasis, which is an exciting new target pathway for cancer treatment. Both scientific developments will be presented as posters at the EACR conference in Barcelona Spain on July 7-10 2012.

4 Jul 2012

Cerulean commences dosing in CRLX101-Avastin combination study for metastatic renal cell carcinoma

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 1b/2a study of its lead product candidate, CRLX101, in combination with Avastin, in metastatic renal cell carcinoma (mRCC) patients. The company also announced the completion of enrollment of its randomized Phase 2 study in advanced non-small cell lung cancer.

2 Jul 2012

New signal transduction pathway might be fruitful target for cancer drugs

Researchers at the University of California, San Diego School of Medicine have uncovered a new signal transduction pathway specifically devoted to the regulation of alternative RNA splicing, a process that allows a single gene to produce or code multiple types of protein variants. The discovery, published in the June 27, 2012 issue of Molecular Cell, suggests the new pathway might be a fruitful target for new cancer drugs.

22 Jun 2012

Cancer publishes Aeterna Zentaris' perifosine Phase 2 trials in RCC

Aeterna Zentaris Inc. today announced that data from two Phase 2 trials in renal cell carcinoma (RCC) for the Company's oral anticancer drug, perifosine, have been published in the June 2012 issue of Cancer, a publication of the American Cancer Society.

18 Jun 2012

Psoriasis TNF-α therapeutic effects mediated by MSC antioxidant reduction

The therapeutic effects of tumor necrosis factor-α inhibitors in psoriasis occur through a reduction in the antioxidant response of mesenchymal stem cells, suggest study findings.

15 Jun 2012

Positive results from Salutaris’ episcleral brachytherapy trial on Wet AMD

Positive results from a trial of episcleral brachytherapy to treat Wet Age-related Macular Degeneration (Wet AMD) were presented today at the ARVO Drug and Gene Delivery to the Back of the Eye Conference.

15 Jun 2012

Ophthotech’s Fovista anti-PDGF combination therapy superior to Lucentis for wet AMD

Ophthotech Corporation today announced results from the first clinical trial to show statistically significant superior efficacy over Lucentis (ranibizumab) monotherapy for the treatment of neovascular age-related macular degeneration (wet AMD).

14 Jun 2012

Promising preliminary data for axitinib in metastatic kidney cancer

Preliminary study data show that axitinib may be an effective first-line treatment for metastatic renal cell carcinoma, particularly in patients with high therapeutic drug exposure and a rise in blood pressure during the first 2 weeks of treatment, researchers report.

12 Jun 2012